Lucy Cureton
Senior Trial Manager
PANORAMIC Trial
Senior Trial Manager
I joined the Primary Care CTU as a Senior Trial Manager in June 2022, predominantly to work on the PANORAMIC study. PANORAMIC is an adaptive platform trial aimed at finding early treatments for COVID-19 by evaluating new antiviral treatments in the community, reducing hospital admissions and easing the burden on the healthcare system. https://www.panoramictrial.org/
During my 17+ years at University of Oxford, I have worked in several different trials units as part of trial management teams, mainly focussing on multicentre CTIMPs across a variety of disciplines. In April 2020, I started working on COVID trials and gained a large amount of knowledge of setting up trials quickly, electronically and under the pressure of a pandemic.
I am a member of the Athena Swan committee representing the CTU, and I am also a proud LGBT+ Ally. 
Key publications
-
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Journal article
(2025), Efficacy and Mechanism Evaluation, 1 - 2
Recent publications
-
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42
-
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48
-
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Journal article
(2025), Efficacy and Mechanism Evaluation, 1 - 2
-
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Journal article
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44
-
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.
Journal article
Png ME. et al, (2024), Br J Gen Pract